Target intelligence / Profile preview

Alpha-hemolysin (Hla)

Target
Hla
Molecular classification
Pore-forming toxin, Bacterial toxin, Beta-barrel pore-forming protein, Integral membrane protein
01

Overview

Alpha-hemolysin is a pore-forming toxin produced by the bacterium *Staphylococcus aureus*. It is synthesized as a 293-residue, water-soluble monomer that binds to susceptible cell membranes, where seven monomers assemble into a heptameric beta-barrel pore. This pore formation disrupts cellular membrane integrity, causing leakage of ions and metabolites, resulting in cell death via either apoptosis or necrosis depending on concentration. Alpha-hemolysin plays a central role in the pathogenesis of S. aureus infections by lysing host cells (including erythrocytes and immune cells), contributing to tissue destruction, immune evasion, and disease severity. It is also widely used as a biotechnological nanopore tool in single-molecule sequencing research[1][2][4][5][7][8].

Other names
Alpha-toxinStaphylococcal alpha-toxinStaphylococcus aureus alpha-toxinHly
02

Mechanism of action

Binding to host cell membranes (specific receptor not fully identified) Oligomerization (usually as a heptamer) to form a transmembrane beta-barrel pore Pore formation results in uncontrolled ion flux, cell lysis, apoptosis (at low concentrations), and necrosis (at high concentrations)[1][2][4][5][8].

03

Biological functions

Cell lysisPore formation in host cell membranesCytotoxicityDisruption of cellular ion gradientsInduction of apoptosis and necrosis
04

Disease associations

Infection (notably, contributing to the pathogenesis of Staphylococcus aureus infections)Tissue damageImmune evasion
05

Safety considerations

Potent cytotoxicity limits direct therapeutic useBroad activity may damage host tissues, leading to safety challenges for inhibitors (unintended immune modulation, off-target effects)Potential immunogenicity in anti-toxin strategies[5]
06

Interacting drugs

No clinically approved drugs are specifically listed; experimental inhibitors and engineered neutralizing antibodies exist, but none are standard therapeutics[3][5].
07

Biomarkers

Presence of anti-alpha-hemolysin antibodies may indicate exposure to Staphylococcus aureus[5]Alpha-hemolysin gene (hla) as marker for virulent S. aureus strains

Beyond the preview

Go deeper on Alpha-hemolysin (Hla).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-hemolysin (Hla).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call